Publication:
Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

dc.date.accessioned 2018-09-14T11:15:03Z
dc.date.available 2017-02-28T23:13:49Z
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2016-07-05 en_US
dc.date.available 2018-09-14T11:15:03Z
dc.date.issued 2016-08-19 en_US
dc.description.abstract Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1) were largely ZIKV-specific and were used to develop a serological diagnostic tool. In contrast, antibodies against E protein domain I/II (EDI/II) were cross-reactive and, although poorly neutralizing, potently enhanced ZIKV and DENV infection in vitro and lethally enhanced DENV disease in mice. Memory T cells against NS1 or E proteins were poorly cross-reactive, even in donors preexposed to DENV. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious virus. An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy.
dc.identifier.uri https://demo7.dspace.org/handle/10673/176
dc.language English en_US
dc.title Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection en_US
dc.type Journal Article
dspace.entity.type Publication
relation.isAuthorOfPublication b1b2c768-bda1-448a-a073-fc541e8b24d9
Files
Collections